Leadership & History

An active leader in the pharmaceutical marketplace for more than 20 years, Stuart co-founded QuVa Pharma in 2015 with long-standing business partner Peter Jenkins. Under their leadership, QuVa has experienced consistent year-over-year growth and is still rapidly expanding.

Prior to QuVa, the two co-founded JHP Pharmaceuticals, where Stuart served as President and COO from 2007-2010 and CEO from 2011-2014. He was instrumental in establishing JHP as a leading injectable pharmaceutical company in the United States before selling the business in 2014.

Previously, Stuart was President of Mayne Pharma Americas, a unit of Mayne that was focused on the manufacture, development, and sale of generic injectable pharmaceuticals, primarily into the hospital market. He led the Americas activity through a period of significant growth and established Mayne Pharma USA as a stand-alone business, ultimately building the division into one of the leading generic oncology providers in the United States.

Specializing in global corporate development and finance, Peter has focused on the pharmaceutical marketplace for the last 20+ years of his storied career. He co-founded QuVa Pharma in 2015 with long-standing business partner Stuart Hinchen. Under their leadership, the firm has experienced consistent year-over-year growth and is still rapidly expanding.

Prior to QuVa, the two co-founded JHP Pharmaceuticals, where Peter served as CEO from 2007-2010 and CDO from 2011-2014, increasing JHP’s portfolio through development and manufacturing partnerships. He helped establish JHP as a leading injectable pharmaceutical company before selling the company in 2014.

Previously, Peter served as CDO of Mayne Group and a Director of Mayne Pharma, where he was instrumental in the acquisition of the largest sterile compounding business in the UK and the acquisition and construction of several FDA-approved pharmaceutical manufacturing facilities. During his tenure, he managed business and product development groups in the U.S., Europe, India, and Australia, and was responsible for all corporate development activities.

As part of QuVa’s executive leadership team, Robert manages QuVa’s finances, including planning, forecasting, analysis, and risk management, among other responsibilities. Additionally, he has responsibility for QuVa's Information Technology department. Robert is a Certified Public Accountant and a Chartered Financial Analyst with extensive public company accounting experience and previous CFO roles. Before joining QuVa, Robert was CFO of Sunnova Energy International, Spark Energy, Inc., and Emerge Energy Services LP. Earlier in his career, Robert was an investment banker, equity research analyst, and private equity officer. 

Robert received his MBA from the University of Pennsylvania’s Wharton School, his Bachelor of Arts degree from Princeton University, and a Certificate in the Accountancy Program from the B.T. Bauer School of Business at the University of Houston.

Ryan Sullivan directs QuVa’s legal and healthcare compliance efforts and serves as legal advisor and secretary to the board of directors. Ryan has over 14 years of experience in the pharmaceutical space. Before joining QuVa, Ryan served as the General Counsel and Secretary of Intercept Pharmaceuticals, where he was responsible for all corporate governance, SEC reporting, litigation, intellectual property, and other legal matters.  Prior to that, he served as General Counsel and Secretary of Anacor Pharmaceuticals, whereas the company’s first in-house attorney, he was responsible for all legal matters and establishing scalable legal and healthcare compliance functions. Ryan also served in several positions of increasing responsibility at Warner Chilcott and practiced in the New York corporate law group of Cahill Gordon & Reindel.

Ryan received his Bachelor of Science from Cornell University and his J.D. from Cornell Law School.

Mike has been in the healthcare field for the last 22 years and has a diverse and extensive commercial background in Sales and Marketing. He joined QuVa in 2017 from having previously led Sales and Marketing organizations at pharmaceutical companies Pfizer, Alexion, and Mylan. He has deep experience across generic, branded, and biosimilar pharmaceutical markets and customers that span: Hospitals & Health Systems, ASCs & Clinics, Specialty Pharmacy, Payer, GPO, and Wholesaler & Distributor.

Mike is responsible for leading QuVa Pharma’s Sales and National Accounts; corporate, product, and services Marketing; and internal and external Corporate Communications.

Having more than 30 years of pharmaceutical experience, David is knowledgeable in cGMPs and specializes in parenteral drug manufacturing, specifically with Quality and Research & Development. Prior to joining QuVa Pharma, David held leadership roles in Quality and Research & Development with Par, JHP Pharmaceuticals, and Hospira supporting the manufacturing of sterile injectables. David has additional leadership experience in quality roles with Johnson & Johnson, Pfizer, Pharmacia, and Upjohn supporting the pharmaceutical manufacturing of API, OTC, and prescription drugs. David has a strong background in operational excellence, driving continuous improvement in processes and people through coaching and training.

Dr. Eschenbacher brings over 20 years of health care pharmacy experience and is responsible for all of QuVa’s pharmacy and clinical operations. She also oversees compliance activities including DEA and State Board of Pharmacy responsibilities. Previously, she has held roles as the Chief Pharmacy Officer for Ascension, served as Assistant Director of Pharmacy at WakeMed Health & Hospitals, and the Medication Safety Officer for Duke University Hospital.  

Dr. Eschenbacher holds a PharmD from the University of Texas as well as an MBA from The Fuqua School of Business at Duke University. She has been awarded the National Distinguished Service Award by the American Society of Health-System Pharmacists (ASHP) and is also a fellow of ASHP.

Dennis brings decades of experience having previously lead transformational change across supply chain and manufacturing in multiple instances at Catalent, a global pharmaceutical contract development and manufacturing organization.  Previous roles Dennis held at Catalent include VP Global Commercial Operations Consumer Health, VP Global Supply Chain Excellence, VP Global Operations Process and Technology Transformation, and Global Director, Strategic Procurement.

Dennis will be responsible for driving organizational change focusing on improving efficiency, customer experience, and compliance. Additionally, he is responsible for developing innovative solutions to complex manufacturing, operational, and sales/marketing challenges and increasing productivity by optimizing QuVa’s processes and systems.